Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stada Arzneimittel
Pharma
Gilead, Tokyo IPO, China's GLP-1 market—Fierce Pharma Asia
Gilead penned a $1.5 billion cancer deal. A cell therapy firm could end a biotech IPO drought in Tokyo. Novo faces more GLP-1 competition in China.
Angus Liu
Feb 20, 2026 11:12am
Stada sets sights on €85M Saudi Arabia manufacturing hub
Feb 17, 2026 2:28pm
CapVest snaps up German generics maker Stada
Sep 2, 2025 10:12am
German generics maker Stada revives IPO plans: report
Aug 28, 2025 1:00pm
Stada charts strong first half of 2024 as owners weigh options
Aug 28, 2024 4:25pm
Stada in 'exploratory' phase of potential sale: CEO
Aug 15, 2023 2:14pm
